LAIR2 and neoplasm: To date, tumor-directed delivery of IL-15/4-1BBL (scFv anti-FAP) (34, 35), IL-2/TNF (scFv anti-EDA) (36) and IL-2/IL-12 (scFv-Fc anti-CD30, LAIR2) (37, 38), has shown significant therapeutic effects in preclinical tumor mouse models.